Arrowhead Pharmaceuticals Patent for AATD Treatment

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted Arrowhead Pharmaceuticals, Inc. a patent (US12582668B2) for methods of treating alpha-1 antitrypsin deficiency (AATD) using pharmaceutical compositions containing AAT RNAi agents. The patent filing date was June 5, 2020, and it is scheduled to be granted on March 24, 2026.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582668B2 to Arrowhead Pharmaceuticals, Inc. This patent covers methods for treating alpha-1 antitrypsin deficiency (AATD) in human patients using pharmaceutical compositions that include AAT RNAi agents. The treatment is specifically aimed at liver diseases associated with AAT deficiency, such as chronic hepatitis, cirrhosis, and fibrosis.

This is a grant of intellectual property and does not impose new regulatory obligations on other entities. However, it signifies a new patented therapeutic approach in the AATD treatment space. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in RNAi therapies or AATD treatments, should be aware of this patent's existence and scope, as it may impact their research, development, and commercialization activities.

Source document (simplified)

← USPTO Patent Grants

Methods for the treatment of alpha-1 antitrypsin deficiency (AATD)

Grant US12582668B2 Kind: B2 Mar 24, 2026

Assignee

Arrowhead Pharmaceuticals, Inc.

Inventors

Bruce Given, Dawn Christianson, James C. Hamilton, Zhen Li, Rui Zhu, Christine I. Wooddell, Tao Pei

Abstract

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.